Ferrous Ascorbate 10mg, Folic Acid 100mcg & Zinc 2.5mg Drops are a multi-component liquid formulation containing Ferrous Ascorbate, Folic Acid, and Zinc in defined quantities. Developing a combination of mineral and vitamin ingredients in a drops dosage form requires controlled raw-material selection, accurate low-dose dispensing, suitable liquid-base development, uniform mixing, and reliable dropper performance. For pharmaceutical companies expanding their pediatric and nutritional product portfolio, this formulation can be incorporated into a structured PCD Pharma Franchise range with appropriate manufacturing specifications and quality documentation.
The formulation contains Ferrous Ascorbate 10mg, Folic Acid 100mcg, and Zinc 2.5mg. Since these ingredients have different concentrations and physicochemical characteristics, formulation development requires particular attention to solubility, dispersion, stability, pH, and compatibility.
Ferrous Ascorbate contributes the iron component, while Folic Acid and Zinc are incorporated at their specified quantities. The comparatively low concentration of Folic Acid makes accurate dispensing and uniform distribution especially important during batch manufacturing.
The liquid vehicle and supporting excipients are selected according to the formulation design. Depending on the approved composition, these may include purified water, sweetening agents, flavoring materials, stabilizers, viscosity modifiers, preservatives where appropriate, and other pharmaceutical excipients.
Preformulation studies can be performed to assess the compatibility of the three nutritional ingredients with one another and with the proposed excipient system. Solubility behavior, pH compatibility, physical appearance, and stability characteristics can be evaluated before finalizing the formulation.
Raw-material dispensing is a critical stage in manufacturing Ferrous Ascorbate 10mg, Folic Acid 100mcg & Zinc 2.5mg Drops. Each ingredient is weighed according to the approved batch formula, with additional verification for low-quantity components.
Folic Acid at 100mcg represents a relatively small quantity within the formulation. Controlled premixing or preparation of a suitable concentrated intermediate may be considered during manufacturing to support uniform distribution throughout the final batch.
Ferrous Ascorbate and Zinc-containing ingredients should also be handled according to their specified physical and chemical characteristics. Appropriate weighing, material identification, and controlled transfer procedures help minimize formulation variability.
Raw materials may undergo suitable sieving or pre-processing where required. The manufacturing sequence is established to promote uniform incorporation of all components into the liquid vehicle.
Controlled addition and mixing are important because localized concentration differences can affect the uniformity of individual portions of the finished liquid. Batch sampling at defined stages can therefore be incorporated into the manufacturing process.
The liquid base is prepared according to the approved manufacturing procedure. Water-soluble excipients may be dissolved separately before being transferred into the main manufacturing vessel. Other components can then be incorporated in a predetermined sequence.
Ferrous Ascorbate, Folic Acid, and Zinc are added under controlled mixing conditions appropriate to their formulation characteristics. Agitation speed and mixing duration are established during product development to achieve a homogeneous liquid system.
If the formulation is designed as a true solution, complete dissolution of the relevant ingredients is monitored. If any component requires dispersion rather than complete dissolution, suitable homogenization and suspension-control techniques may be incorporated into the process.
Parameters such as pH, temperature, mixing speed, and processing time can influence the physical stability of the formulation. These parameters should therefore remain within established process ranges.
After final mixing, the bulk formulation may undergo suitable filtration or clarification where compatible with the product design. The finished bulk is then transferred to the filling stage under controlled conditions.
The drops dosage form requires more than just a uniform liquid formulation. The delivery system must also provide consistent dispensing performance. The dropper or dispensing device is therefore an important component of product development.
Fill-volume control is maintained during the filling process to ensure that each container receives the specified quantity. Container and closure components should be compatible with the formulation and capable of maintaining appropriate product integrity.
Finished-product evaluation may include appearance, color, odor, pH, viscosity, fill volume, and homogeneity. Where the formulation contains suspended material, sedimentation and redispersibility may also be evaluated according to the established specification.
Drop size and dispensing consistency can be assessed using suitable product-specific procedures. The objective is to establish reproducible delivery behavior across individual containers and throughout the intended product lifecycle.
Container-closure integrity can also be evaluated to minimize leakage and environmental exposure. Proper filling, capping, and sealing procedures are maintained through controlled packaging operations.
Quality control for Ferrous Ascorbate 10mg, Folic Acid 100mcg & Zinc 2.5mg Drops includes analytical evaluation of the individual components and physical characteristics of the finished liquid.
Suitable validated analytical procedures may be used for identification and assay of Ferrous Ascorbate, Folic Acid, and Zinc according to the approved product specifications. Analytical sensitivity is particularly relevant for Folic Acid because of its comparatively low concentration.
Depending on the formulation, additional testing may include pH, viscosity, fill volume, microbial quality, appearance, homogeneity, and relevant degradation or impurity parameters.
Stability studies are performed under defined storage conditions
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech